IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis - Archive ouverte HAL Access content directly
Journal Articles Mucosal Immunology Year : 2016

IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis

(1, 2, 3, 4) , (1, 2) , (1, 2) , (3, 5, 6) , (5) , (1, 2) , (7) , (1, 2) , (1, 2) , (1, 2) , (8) , (9, 10) , (1, 2) , (11, 12) , (9, 13) , (1, 2, 3, 4)
1
2
3
4
5
6
7
8
9
10
11
12
13

Abstract

Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel diseases (IBDs), are characterized by high levels of IL-22 production. Rodent studies revealed that this cytokine is protective during colitis but whether this is true in IBDs is unclear. We show here that levels of the soluble inhibitor of IL-22, interleukin 22-binding protein (IL-22BP), are significantly enhanced during IBDs owing to increased numbers of IL-22BP-producing eosinophils, that we unexpectedly identify as the most abundant source of IL-22BP protein in human gut. In addition, using IL-22BP-deficient rats, we confirm that endogenous IL-22BP is effective at blocking protective actions of IL-22 during acute colitis. In conclusion, our study provides new important insights regarding the biology of IL-22 and IL-22BP in the gut and indicates that protective actions of IL-22 are likely to be suboptimal in IBDs thus making IL-22BP a new relevant therapeutic target.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02150949 , version 1 (07-06-2019)

Identifiers

Cite

J. C. Martin, G Bériou, M Heslan, C. Bossard, A Jarry, et al.. IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis. Mucosal Immunology, 2016, 9 (2), pp.539-549. ⟨10.1038/mi.2015.83⟩. ⟨inserm-02150949⟩
45 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More